Skip to main content
PMC home page
Emerging Infectious Diseases logoLink to Emerging Infectious Diseases
. 2001;7(3 Suppl):526–528. doi: 10.3201/eid0707.017708

Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence?

F R Mooi 1, I H van Loo 1, A J King 1
PMCID: PMC2631860  PMID: 11485646

Abstract

In the Netherlands, as in many other western countries, pertussis vaccines have been used extensively for more than 40 years. Therefore, it is conceivable that vaccine-induced immunity has affected the evolution of Bordetella pertussis. Consistent with this notion, pertussis has reemerged in the Netherlands, despite high vaccination coverage. Further, a notable change in the population structure of B. pertussis was observed in the Netherlands subsequent to the introduction of vaccination in the 1950s. Finally, we observed antigenic divergence between clinical isolates and vaccine strains, in particular with respect to the surface-associated proteins pertactin and pertussis toxin. Adaptation may have allowed B. pertussis to remain endemic despite widespread vaccination and may have contributed to the reemergence of pertussis in the Netherlands.

Full Text

The Full Text of this article is available as a PDF (401.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrews R., Herceg A., Roberts C. Pertussis notifications in Australia, 1991 to 1997. Commun Dis Intell. 1997 May 29;21(11):145–148. [PubMed] [Google Scholar]
  2. Cassiday P., Sanden G., Heuvelman K., Mooi F., Bisgard K. M., Popovic T. Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999. J Infect Dis. 2000 Oct 9;182(5):1402–1408. doi: 10.1086/315881. [DOI] [PubMed] [Google Scholar]
  3. Cherry J. D. Epidemiological, clinical, and laboratory aspects of pertussis in adults. Clin Infect Dis. 1999 Jun;28 (Suppl 2):S112–S117. doi: 10.1086/515058. [DOI] [PubMed] [Google Scholar]
  4. Cherry J. D., Gornbein J., Heininger U., Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine. 1998 Dec;16(20):1901–1906. doi: 10.1016/s0264-410x(98)00226-6. [DOI] [PubMed] [Google Scholar]
  5. De Magistris M. T., Di Tommaso A., Domenighini M., Censini S., Tagliabue A., Oksenberg J. R., Steinman L., Judd A. K., O'Sullivan D., Rappuoli R. Interaction of the pertussis toxin peptide containing residues 30-42 with DR1 and the T-cell receptors of 12 human T-cell clones. Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2990–2994. doi: 10.1073/pnas.89.7.2990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. De Serres G., Boulianne N., Douville Fradet M., Duval B. Pertussis in Quebec: ongoing epidemic since the late 1980s. Can Commun Dis Rep. 1995 Mar 15;21(5):45–48. [PubMed] [Google Scholar]
  7. Everest P., Li J., Douce G., Charles I., De Azavedo J., Chatfield S., Dougan G., Roberts M. Role of the Bordetella pertussis P.69/pertactin protein and the P.69/pertactin RGD motif in the adherence to and invasion of mammalian cells. Microbiology. 1996 Nov;142(Pt 11):3261–3268. doi: 10.1099/13500872-142-11-3261. [DOI] [PubMed] [Google Scholar]
  8. Mastrantonio P., Spigaglia P., van Oirschot H., van der Heide H. G., Heuvelman K., Stefanelli P., Mooi F. R. Antigenic variants in Bordetella pertussis strains isolated from vaccinated and unvaccinated children. Microbiology. 1999 Aug;145(Pt 8):2069–2075. doi: 10.1099/13500872-145-8-2069. [DOI] [PubMed] [Google Scholar]
  9. Mooi F. R., He Q., van Oirschot H., Mertsola J. Variation in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland. Infect Immun. 1999 Jun;67(6):3133–3134. doi: 10.1128/iai.67.6.3133-3134.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Mooi F. R., van Oirschot H., Heuvelman K., van der Heide H. G., Gaastra W., Willems R. J. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun. 1998 Feb;66(2):670–675. doi: 10.1128/iai.66.2.670-675.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Nei M., Tajima F. DNA polymorphism detectable by restriction endonucleases. Genetics. 1981 Jan;97(1):145–163. doi: 10.1093/genetics/97.1.145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Ochman H., Wilson A. C. Evolution in bacteria: evidence for a universal substitution rate in cellular genomes. J Mol Evol. 1987;26(1-2):74–86. doi: 10.1007/BF02111283. [DOI] [PubMed] [Google Scholar]
  13. Streisinger G., Owen J. Mechanisms of spontaneous and induced frameshift mutation in bacteriophage T4. Genetics. 1985 Apr;109(4):633–659. doi: 10.1093/genetics/109.4.633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Wright S. W., Decker M. D., Edwards K. M. Incidence of pertussis infection in healthcare workers. Infect Control Hosp Epidemiol. 1999 Feb;20(2):120–123. doi: 10.1086/501593. [DOI] [PubMed] [Google Scholar]
  15. de Melker H. E., Conyn-van Spaendonck M. A., Rümke H. C., van Wijngaarden J. K., Mooi F. R., Schellekens J. F. Pertussis in The Netherlands: an outbreak despite high levels of immunization with whole-cell vaccine. Emerg Infect Dis. 1997 Apr-Jun;3(2):175–178. doi: 10.3201/eid0302.970211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. van Loo I. H., van der Heide H. G., Nagelkerke N. J., Verhoef J., Mooi F. R. Temporal trends in the population structure of Bordetella pertussis during 1949-1996 in a highly vaccinated population. J Infect Dis. 1999 Apr;179(4):915–923. doi: 10.1086/314690. [DOI] [PubMed] [Google Scholar]

Articles from Emerging Infectious Diseases are provided here courtesy of Centers for Disease Control and Prevention

RESOURCES